Suppr超能文献

阵发性与持续性心房颤动患者抗凝治疗处方的差异。

Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation.

作者信息

Hsu Jonathan C, Chan Paul S, Tang Fengming, Maddox Thomas M, Marcus Gregory M

机构信息

Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, University of California, San Diego.

Mid America Heart Institute, Kansas City, Mo.

出版信息

Am J Med. 2015 Jun;128(6):654.e1-654.e10. doi: 10.1016/j.amjmed.2014.11.035. Epub 2014 Dec 29.

Abstract

BACKGROUND

Patients with paroxysmal and persistent atrial fibrillation experience a similar risk of thromboembolism. Therefore, consensus guidelines recommend anticoagulant therapy in those at risk for thromboembolism irrespective of atrial fibrillation classification. We sought to examine whether there are differences in rates of appropriate oral anticoagulant treatment among patients with paroxysmal vs persistent atrial fibrillation in real-world cardiology practices.

METHODS

We studied 71,316 outpatients with atrial fibrillation and intermediate to high thromboembolic risk (CHADS2 score ≥2) enrolled in the American College of Cardiology PINNACLE Registry between 2008 and 2012. Using hierarchical modified Poisson regression models adjusted for patient characteristics, we examined whether anticoagulant treatment rates differed between patients with paroxysmal vs persistent atrial fibrillation.

RESULTS

The majority of outpatients (78.4%, n = 55,905) had paroxysmal atrial fibrillation. In both unadjusted and multivariable adjusted analyses, patients with paroxysmal atrial fibrillation were less frequently prescribed oral anticoagulant therapy than those with persistent atrial fibrillation (50.3% vs 64.2%; adjusted risk ratio [RR] 0.74; 95% confidence interval [CI], 0.72-0.76). Instead, patients with paroxysmal atrial fibrillation were prescribed more frequently only antiplatelet therapy (35.1% vs 25.0%; adjusted RR 1.77; 95% CI, 1.69-1.86) or neither antiplatelet nor anticoagulant therapy (14.6% vs 10.8%; adjusted RR 1.35; 95% CI, 1.26-1.44; P < .0001 for differences across all 3 comparisons).

CONCLUSIONS

In a large, real-world cardiac outpatient population, patients with paroxysmal atrial fibrillation with a moderate to high risk of stroke were less likely to be prescribed appropriate oral anticoagulant therapy and more likely to be prescribed less effective or no therapy for thromboembolism prevention.

摘要

背景

阵发性和持续性心房颤动患者发生血栓栓塞的风险相似。因此,共识指南建议对有血栓栓塞风险的患者进行抗凝治疗,而不考虑心房颤动的分类。我们试图研究在现实世界的心脏病学实践中,阵发性与持续性心房颤动患者接受适当口服抗凝治疗的比例是否存在差异。

方法

我们研究了2008年至2012年期间纳入美国心脏病学会PINNACLE注册研究的71316例有中度至高度血栓栓塞风险(CHADS2评分≥2)的心房颤动门诊患者。使用针对患者特征进行调整的分层修正泊松回归模型,我们研究了阵发性与持续性心房颤动患者的抗凝治疗率是否存在差异。

结果

大多数门诊患者(78.4%,n = 55905)患有阵发性心房颤动。在未调整和多变量调整分析中,阵发性心房颤动患者接受口服抗凝治疗的频率低于持续性心房颤动患者(50.3%对64.2%;调整风险比[RR]0.74;95%置信区间[CI],0.72 - 0.76)。相反,阵发性心房颤动患者更常仅接受抗血小板治疗(35.1%对25.0%;调整RR 1.77;95%CI,1.69 - 1.86)或既不接受抗血小板治疗也不接受抗凝治疗(14.6%对10.8%;调整RR 1.35;95%CI,1.26 - 1.44;所有3项比较的差异P <.0001)。

结论

在一个大型的现实世界心脏门诊人群中,有中度至高度卒中风险的阵发性心房颤动患者接受适当口服抗凝治疗的可能性较小,而接受预防血栓栓塞效果较差或不接受治疗的可能性较大。

相似文献

8
10
The treatment of paroxysmal atrial fibrillation in UK primary care.英国初级保健中的阵发性心房颤动治疗。
Heart. 2017 Oct;103(19):1502-1507. doi: 10.1136/heartjnl-2016-310927. Epub 2017 Jun 1.

引用本文的文献

本文引用的文献

2
Subclinical atrial fibrillation and the risk of stroke.无症状性心房颤动与卒中风险。
N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575.
3
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
7
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验